2017
DOI: 10.1371/journal.pone.0185438
|View full text |Cite
|
Sign up to set email alerts
|

Field trial of efficacy of the Leish-tec® vaccine against canine leishmaniasis caused by Leishmania infantum in an endemic area with high transmission rates

Abstract: BackgroundBecause domestic dogs are reservoir hosts for visceral leishmaniasis (VL) in Brazil, one of the approaches used to reduce human disease incidence is to cull infected dogs. However, the results of controlled intervention trials based on serological screening of dogs and killing of seropositive animals are equivocal. A prophylactic vaccine to protect dogs from being infectious to the sand fly vector could be an effective strategy to provide sustained control. Here, we investigated whether a currently l… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

4
46
0

Year Published

2018
2018
2023
2023

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 56 publications
(50 citation statements)
references
References 48 publications
4
46
0
Order By: Relevance
“…In fact, the incidence of canine VL was 42% in controls and 27% in vaccinated dogs (122). Furthermore, 43% of the vaccinated dogs developed the disease over time, and seroconversion was higher in vaccinated dogs than in controls (122).…”
Section: Anti-leishmania Licensed Vaccinesmentioning
confidence: 95%
See 3 more Smart Citations
“…In fact, the incidence of canine VL was 42% in controls and 27% in vaccinated dogs (122). Furthermore, 43% of the vaccinated dogs developed the disease over time, and seroconversion was higher in vaccinated dogs than in controls (122).…”
Section: Anti-leishmania Licensed Vaccinesmentioning
confidence: 95%
“…When parasitologically and xenodiagnosis-positive cases were considered, vaccine efficacy was 58.1% (121). While the first field trial of Leishtec R was performed in a low infective pressure area, a second Phase III trial was run in a high transmission rate area, and the vaccine efficacy was only 35.7% (122). In fact, the incidence of canine VL was 42% in controls and 27% in vaccinated dogs (122).…”
Section: Anti-leishmania Licensed Vaccinesmentioning
confidence: 99%
See 2 more Smart Citations
“…Ribosomal proteins (e.g., P0), metabolic enzymes (e.g., TPI), stress-related proteins (e.g., HSP), antioxidant-machinery components (e.g., TPR), and even hypothetical proteins ( Table 1) are found among them. One of these candidates, L. donovani A2, is today a licensed veterinary vaccine against leishmaniasis in Brazil-LeishTec ® (that needs however to be optimized, according to a recent efficacy field trial performed in an endemic area with high transmission rates [92]). In the past few years, the development of vaccine candidates against leishmaniasis became more refined and rationale based, following the trends of twenty-first-century vaccinology [93].…”
Section: Second-generation Vaccine Candidatesmentioning
confidence: 99%